+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Bioequivalence trial of orally disintegrating mirtazapine tablets and conventional oral mirtazapine tablets in healthy volunteers



Bioequivalence trial of orally disintegrating mirtazapine tablets and conventional oral mirtazapine tablets in healthy volunteers



Clinical Drug Investigation 21(6): 437-442



Background: Mirtazapine is a well tolerated and effective antidepressant agent that is currently available as a tablet. Patient compliance with antidepressant treatment that has to be swallowed is very low. Therefore, an orally disintegrating formulation of mirtazapine, which dissolves in the mouth, was devised to improve patient compliance. Objective: To establish the bioequivalence of these two formulations of mirtazapine. Design: Under fasting conditions, participants received in a two-way, single-dose crossover fashion the orally disintegrating formulation of mirtazapine (30mg tablet) (Remeron(R) SoltabTM) and the marketed formulation of mirtazapine (30mg tablet) (Remeron(R)), separated by a 2-week washout period. Patients and Participants: 40 healthy individuals (20 men, 20 women). Main Outcome Measures and Results: The ratio of geometric means (new formulation:marketed formulation) of pharmacokinetic parameters was 1.072 for the peak concentration of mirtazapine (Cmax) (90% confidence interval (CI) 0.948 to 1.212), 1.103 for the area under the concentration-time curve from zero to the last time-point with a measurable concentration (AUC0-tlast) (90% CI 1.052 to 1.156) and 1.101 for the area under the concentration-time curve from zero to infinity (AUC0-infin) (90% CI 1.049 to 1.156). The two study formulations were found to be bioequivalent, as all the 90% CIs fell within the acceptance range of 0.80 to 1.25. The adverse events reported were not unexpected and were more likely related to the protocol than to the drug. Somnolence was the most common adverse event, followed by fatigue and dizziness. No clinically significant effects on laboratory safety parameters, vital signs or ECG were observed. Conclusion: A new orally disintegrating formulation of mirtazapine was shown to be bioequivalent to the marketed tablet formulation. This formulation may increase compliance in depressed patients and therefore offer an appropriate alternative for depressed patients currently taking tablets.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 010242171

Download citation: RISBibTeXText

DOI: 10.2165/00044011-200121060-00007


Related references

Bioavailability and bioequivalence of ondansetron orally disintegrating tablets and conventional tablets. Fudan Xuebao 32(1): 55-58, 2005

Bioequivalence of a single 10-mg dose of finasteride 5-mg oral disintegrating tablets and standard tablets in healthy adult male Han Chinese volunteers: a randomized sequence, open-label, two-way crossover study. Clinical Therapeutics 31(10): 2242-2248, 2010

Formulation studies for mirtazapine orally disintegrating tablets. Drug Development and Industrial Pharmacy 42(6): 1008-1017, 2016

Mirtazapine orally disintegrating tablets in depressed patients who are at least 50 years of age. Pharmacotherapy 22(10): 1369, 2002

Mirtazapine Orally Disintegrating Tablets Versus Venlafaxine Extended Release. Journal of Clinical Psychopharmacology 26(1): 75-78, 2006

Development and evaluation of orally disintegrating tablets comprising taste-masked mirtazapine granules. Pharmaceutical Development and Technology 23(5): 488-495, 2017

Mirtazapine orally disintegrating tablets in depressed nursing home residents 85 years of age and older. International Journal of Geriatric Psychiatry 21(9): 898-901, 2006

Sexual function of patients with major depression treated with mirtazapine orally disintegrating tablets or sertraline. Journal of Affective Disorders 78(Supplement 1): S114-S115, 2004

Open-label study of mirtazapine orally disintegrating tablets in depressed patients in the nursing home. Current Medical Research and Opinion 19(8): 737-746, 2003

Factor analysis on onset of therapeutic effect of mirtazapine orally disintegrating tablets versus sertraline. Journal of Affective Disorders 78(Supplement 1): S122, 2004

Mirtazapine orally disintegrating tablets versus venlafaxine extended release: a double-blind, randomized multicenter trial comparing the onset of antidepressant response in patients with major depressive disorder. Journal of Clinical Psychopharmacology 26(1): 75-78, 2006

Are there predictors of outcome in depressed elderly nursing home residents during treatment with mirtazapine orally disintegrating tablets?. International Journal of Geriatric Psychiatry 22(10): 999-1003, 2007

Efficacy, tolerability, and preference of mirtazapine orally disintegrating tablets in depressed patients: a 17-week naturalistic study in Lithuania. Medicina 45(10): 778-784, 2010

Multi-center, open label, naturalistic study of mirtazapine orally disintegrating tablets in depressed nursing home patients. Pharmacotherapy 22(10): 1342, 2002

Bioequivalence of clozapine orally disintegrating 100-mg tablets compared with clozapine solid oral 100-mg tablets after multiple doses in patients with schizophrenia. Clinical Drug Investigation 28(4): 231-239, 2008